Dorsey & Whitney Trust CO LLC cut its stake in shares of Astrazeneca PLC (NYSE:AZN) by 15.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 11,217 shares of the company’s stock after selling 2,098 shares during the period. Dorsey & Whitney Trust CO LLC’s holdings in Astrazeneca were worth $380,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. WFG Advisors LP raised its stake in Astrazeneca by 36.0% during the 2nd quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock valued at $127,000 after acquiring an additional 984 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its stake in Astrazeneca by 71.2% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock valued at $145,000 after acquiring an additional 1,769 shares during the last quarter. Quadrant Capital Group LLC increased its position in Astrazeneca by 18.4% during the 2nd quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock worth $147,000 after purchasing an additional 846 shares during the period. Westport Asset Management Inc. acquired a new position in Astrazeneca during the 2nd quarter worth approximately $170,000. Finally, First Interstate Bank increased its position in Astrazeneca by 10.3% during the 2nd quarter. First Interstate Bank now owns 5,127 shares of the company’s stock worth $175,000 after purchasing an additional 480 shares during the period. 14.75% of the stock is owned by hedge funds and other institutional investors.

AZN has been the topic of several recent analyst reports. Natixis upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, September 6th. Argus reiterated a “buy” rating and set a $35.00 target price on shares of Astrazeneca in a research report on Friday, September 1st. Investec upgraded Astrazeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Piper Jaffray Companies reiterated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, August 9th. Finally, Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a research report on Friday, September 22nd. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company. Astrazeneca currently has an average rating of “Hold” and an average target price of $34.20.

Shares of Astrazeneca PLC (NYSE AZN) opened at $33.52 on Wednesday. The firm has a market capitalization of $83,550.00, a P/E ratio of 8.08, a P/E/G ratio of 3.20 and a beta of 0.79. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09. Astrazeneca PLC has a fifty-two week low of $25.55 and a fifty-two week high of $35.60.

Astrazeneca (NYSE:AZN) last released its quarterly earnings results on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.55. The business had revenue of $6.23 billion for the quarter, compared to analysts’ expectations of $6 billion. Astrazeneca had a return on equity of 34.02% and a net margin of 15.90%. The company’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.32 EPS. analysts expect that Astrazeneca PLC will post 1.93 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Dorsey & Whitney Trust CO LLC Has $380,000 Holdings in Astrazeneca PLC (AZN)” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/29/dorsey-whitney-trust-co-llc-has-380000-holdings-in-astrazeneca-plc-azn.html.

Astrazeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).

Institutional Ownership by Quarter for Astrazeneca (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.